Mitsubishi UFJ Trust & Banking Corp Trims Position in Bristol Myers Squibb Company $BMY

Key Points

• Mitsubishi UFJ Trust & Banking Corp cut its stake in Bristol Myers Squibb by 40.1% in Q4, selling 1,069,020 shares and retaining 1,599,604 shares (about 0.08% of the company) worth $86.29 million.
• EVP David V. Elkins sold 30,000 BMY shares on April 1 at an average price of $61.67, reducing his position by 15.85% and leaving him with 159,248 shares.
• Bristol Myers Squibb announced a $0.63 quarterly dividend (annualized $2.52, yield 4.4%; ex-dividend Apr 2, payable May 1). The company reported Q earnings of $1.26 EPS (miss vs. $1.65) and set FY2026 guidance of 6.05–6.35 EPS (sell-side consensus ~6.28).

Mitsubishi UFJ Trust & Banking Corp decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 40.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,599,604 shares of the biopharmaceutical company's stock after selling 1,069,020 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.08% of Bristol Myers Squibb worth $86,290,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. grew its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp purchased a new position in Bristol Myers Squibb during the 3rd quarter worth $35,000. Finally, JPL Wealth Management LLC bought a new stake in Bristol Myers Squibb during the 3rd quarter valued at $36,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP David V. Elkins sold 30,000 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.05% of the stock is currently owned by company insiders.

Bristol Myers Squibb Trading Down 1.4%

NYSE BMY opened at $57.86 on Tuesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a 50 day moving average price of $59.63 and a 200 day moving average price of $54.31. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The firm has a market cap of $118.13 billion, a PE ratio of 16.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the business earned $1.67 earnings per share. Bristol Myers Squibb's revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, sell-side analysts forecast that Bristol Myers Squibb Company will post 6.28 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 73.04%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a "sector perform" rating and a $60.00 price target on the stock. Piper Sandler restated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Morgan Stanley reaffirmed an "underweight" rating and issued a $40.00 price objective on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Citigroup increased their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "neutral" rating in a report on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Sunday, April 19th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.